Articles On Zelda Therapeutics (ASX:ZLD)

4DMedical could replicate Pro Medicus’ US success Its new tech could revolutionise lung disease diagnostics  Potential Philips deal drives optimism for 4DX Stockhead’s markets guru Eddy Sunarto brings you the latest updates from leading A...

In today’s Australian market, several companies have demonstrated remarkable gains, reflecting a robust performance across various sectors. Here’s an in-depth look at the top gainers: Highcom Limited (ASX:HCL)Highcom Limited has experience...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

ASX 200 ends a weak day down but not way down… just -0.23pc All 11 sectors were generally terrible, but 3 ended higher led by Real Estate Small caps led by DGR, ZLD and MSG, with some BIG gains for the day   On Tuesday local markets wa...

Not much in the way of headline news, but the market plodded along ASX 200 closes down -0.12pc, despite a push for Health and the Goldies Who won the Small Caps race today? Read on to find out…   It’s not been the busiest of news days, bu...

Imricor completes installation of iCMR capital equipment at Lausanne University Hospital in Switzerland PYC Therapeutics says safety data from patient cohort four successfully reviewed with recommendation trial continues Cynata Therapeutic...

Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their cannabinoid products BOD Australia could have the first Schedule 3 CBD product in Australia following positive results from its Phase 2B Ca...

Since TGA’s down-scheduling of CBD last year, no products have been sold in Australia But the race to market has been seemingly won by Bod Science following a ‘landmark update’ Stockhead reached out to BOD’s CEO, Jo Patterson   Amidst gro...

Zelira announced that its diabetic nerve pain drug outperforms Pfizer’s Lyrica Diabetes is a huge market, estimated at a massive US$62 billion in 2022 Stockhead reached out to Zelira’s CEO, Dr. Oludare Odumosu   Diabetes is one of the lea...

The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week   As we head into the...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

The world is experiencing a ‘shroom boom’ Psychedelics are expected to follow in cannabis’ explosive footstep And here’s how the ASX weed stocks have performed, sorted by winners over the past week   For years, people have frowned upon ps...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

The S&P ASX 200 was down 2.5% in May, with mid caps performing the best and small caps lagging blue chips The S&P ASX 200 Information Technology sector performed the best in May, up 11.6% following strong AI interest Wildcat Resou...

Cannabinoid company Zelira Therapeutics (ASX:ZLD) has announced the appointment of Dr Donna Gentile O’Donnell as a non-executive director.

The ASX 200 fell 1.37%, and the bad news kept piling up all day Inflation data knee-capped the market mid-morning, because rate hikes are on the way Two Small Caps hit triple-figure home runs today, which is kinda amazing   Welp… that was...

The market closed lower today, with the ASX 200 down 1.6 per cent to 7,091.3 points. Inflation for the year to April was recorded higher than expected at 6.8 per cent. The news also took a toll on the sectors, spreading a sea of red....

It’s been a pretty miserable day on the ASX share market this Wednesday. The All Ordinaries Index (ASX: XAO) finished at a heavy loss, closing 1.54% lower. But let’s talk about one ASX healthcare share that decidedly bucked the markets wit...

Stockhead’s In-Case-You-Missed-It highlights some of the strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

Shares in Perth-based medical cannabinoid developer Zelira Therapeutics’ (ASX: ZLD) rocketed by than 256 per cent today after the company revealed its diabetic nerve pain drug had delivered what it says are superior results to Lyrica, Pfize...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Perth-based Zelira Therapeutics (ASX: ZLD) has confirmed its cannabinoid-based diabetic nerve pain drug ZLT-L-007 has outperformed Pfizer’s commercially-available medi...

Zelira skyrockets by almost 200% this morning The company said its drug could work better than Lyrica Neurotech was granted a two-year extension for treating ASD patients   Zelira Therapeutics’ (ASX:ZLD) share price almost tripled this mo...

Early 1.37% benchmark jump slides slowly to land at +0.88% Real Estate leads on +1.89%, with Consumer Discretionary in last, down 0.59% Signs of lithium-bearing pegmatites at Kirup boost Kula Gold by 42.6%   Well, it’s that time of the da...

The Swiss government has moved quickly to shore up its uniqueness as a centre of commerce – albeit one where the banks eat each other – and hurriedly green-lit (no pun) plans to legalise the sale and consumption of cannabis in Zurich, Switz...

Zelira Therapeutics (ZLD) raises $1.77 million to progress its clinical trials The funds were raised via a placement to US-based investors at $1 per share, representing a 3 per cent discount to ZLD’s 15-day VWAP on March 10 Zelira say...

ASX weathers a US bank collapse storm to finish the day down just 0.5% XEC Emerging Companies index down 0.84% because it was out partying all weekend. The Goldies take the gongs, after the precious metal jumped more than 1.0%   Looking a...

Twitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on top with CannaCare Health arbitration awarded in their favour Avecho expands CBD soft-gel capsule trials with the Lambert Initiative   Twi...

The ASX recovered from an early stumble to finish the day up-ish Meta wants you to pay $12 a month for the privilege of being a captive audience Some Big Names have had shockers as earnings relentlessly keep rolling in   The benchmark has...

Zelira Therapeutics (ZLD) promotes Greg Blake to the role of Executive Director Mr Blake joined the company in 2020 and has been serving as Vice President, Global Head of Commercial and Partnering After more than 20 years working in t...

Zelira Therapeutics (ZLD) secures US$8.6 million (A$12.3 million) in cornerstone funding from a US-based investor to support its HOPE clinical trials Cantheon Capital will provide the funding via a convertible note arrangement to help Ze...

The ASX 200 fell 0.21% and the ASX XEC slips 1.05% A 8 out of 11 sectors were lower led by Consumer Discretionary down 1.40% Energy sector and stocks rally after Russia announces plans to slash oil production   The ASX 200 dropped 0.21% t...

Zelira Therapeutics (ASX:ZLD) has announced the successful enrolment of 60 patients in the clinical trial of its cannabinoid medicine for diabetic nerve pain.

Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index   It turns out that the lazy stoner stereotype is actually a myth,...

Zelira Therapeutics (ZLD) completes enrolment of two-thirds of patients for its diabetic nerve pain drug trialThe company has now enrolled 40 out of 60 patients in the clinical trial, in which Zelira will go head-to-head against a major pha...

The ASX will rise modestly higher on Thursday Wall Street whipsawed in a volatile day of trading Aussie unemployment data ahead Local shares are set to open modestly higher today. At 8am AEST, the ASX 200 September futures contract is poi...

Just over a month after the collapse of Health House International’s (ASX: HHI) proposed merger with Zelira Therapeutics (ASX: ZLD), cannabidiol (CBD) innovator Creso Pharma (ASX: CPH) has announced the signing of a non-binding term sheet t...

Benchmark sags as Materials sector delivers even more tedious disappointment Coal miners hand back yesterday’s gains as investors tire of Chinese whispers Cannabis offers relief for investors and health stocks climb as well. The ASX has e...

ECS is selling its medicinal cannabis farm in Tasmania Crypto ATMs are now a thing in weed dispensaries in the US Zelira Therapeutics nabs regulatory approval in Germany for insomnia medication Ever fancied your own cannabis farm? Well, t...

The ASX 200 is up, the XEC is up solidly   Energy, resources, materials are back in black  US CPI was a tough read, but not fatal   Australian small caps are trading well over 1.5% higher on Thursday afternoon as mining and energy stocks...

It’s another green day for the Zelira Therapeutics Ltd (ASX: ZLD) share price. The medicinal cannabis stock is currently surging 36.6% higher, bringing its gains for this week alone to a whopping 111%. At the time of writing, the Zelira...

Zelira Therapeutics (ZLD) receives formal approval from the German regulatory authority BfArM for the commercialisation of Zenivol in the country This is a significant milestone for the company as it allows Zelira to expand the availabilit...

The Zelira Therapeutics Ltd (ASX: ZLD) share price has exploded in the past two days. This ASX medicinal cannabis share has risen 49% since market close on 11 July from $1.54 to the current price of $2.30. Since 6 July, the company’s shar...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The Zelira Therapeutics Ltd (ASX: ZLD) share price was put on ice in mid-afternoon trading on Tuesday after it rocketed 28.57%. It followed the company’s request that its shares be placed in an immediate trading halt. Shares in the medic...

The ASX 200 ends flat, XEC sheds 1.6% Gains in healthcare and supermarkets offsets losses for miners, materials, tech and gold ANZ: Consumer confidence is broke; is Belararox IPO of ’22?  The benchmark has given up wee gains to end flat....

Retail and independent cannabis lounges could be opening soon in Vegas Cann Group gets good manufacturing practice (GMP) licence for its Mildura facility Bod plans to launch a low dose CBD schedule 3 product into the Australian market  ...

A "substantial change in market conditions" is behind a mutual decision to terminate a merger of Zelira Therapeutics (ASX: ZLD) and Health House International (ASX: HHI), putting an end to five months of courtship between the two Perth-base...

Zelira Therapeutics (ZLD) mutually agrees to terminate a deal with Health House International In February, the two parties announced a new contract under which Zelira would buy Health House through a scheme of arrangement to expand the mar...